1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Sumitomo Dainippon Pharma Co., Ltd.
  6. Summary
    4506   JP3495000006

SUMITOMO DAINIPPON PHARMA CO., LTD.

(4506)
  Report
Delayed Japan Exchange  -  02:00 2022-08-10 am EDT
1107.00 JPY   +1.84%
08/09Poxel Provides Corporate Update and Reports Cash and Revenue for the Second Quarter and First Half 2022
AQ
08/08Sumitomo Pharma Co., Ltd. - Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis
AQ
08/05SUMITOMO DAINIPPON PHARMA : Jul. 29, 2022 Q1 FY2022 Conference Call transcript (PDF/1,785KB)
PU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Japan Exchange
08/04/2022 08/05/2022 08/08/2022 08/09/2022 08/10/2022 Date
1091(c) 1110(c) 1120(c) 1087(c) 1107 Last
1 016 700 1 093 200 1 093 100 1 103 200 753 300 Volume
+1.77% +1.74% +0.90% -2.95% +1.84% Change
More quotes
Estimated financial data (e)
Sales 2023 549 B 4 070 M 4 070 M
Net income 2023 25 250 M 187 M 187 M
Net Debt 2023 48 352 M 358 M 358 M
P/E ratio 2023 15,0x
Yield 2023 2,58%
Sales 2024 407 B 3 019 M 3 019 M
Net income 2024 -34 417 M -255 M -255 M
Net Debt 2024 18 748 M 139 M 139 M
P/E ratio 2024 -12,7x
Yield 2024 2,48%
Capitalization 432 B 3 200 M 3 200 M
EV / Sales 2023 0,87x
EV / Sales 2024 1,11x
Nbr of Employees 6 987
Free-Float 40,8%
More Financials
Company
Sumitomo Dainippon Pharma Co., Ltd. specializes in development, manufacturing and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceuticals (92.8%): for cardiovascular, gastrointestinal and infectious diseases, central nervous systems disorders and allergies treatment; - other (7.2%): veterinary drugs, food additives, industrial chemical products, etc. Net... 
More about the company
Ratings of Sumitomo Dainippon Pharma Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about SUMITOMO DAINIPPON PHARMA CO., LTD.
08/09Poxel Provides Corporate Update and Reports Cash and Revenue for the Second Quarter and..
AQ
08/08Sumitomo Pharma Co., Ltd. - Myovant Sciences and Pfizer Receive U.S. FDA Approval of MY..
AQ
08/05SUMITOMO DAINIPPON PHARMA : Jul. 29, 2022 Q1 FY2022 Conference Call transcript (PDF/1,785K..
PU
08/03Sumitomo Pharma Co., Ltd. and Eli Lilly Japan K.K. Announces Conclusion of Sales Collab..
CI
08/02SUMITOMO DAINIPPON PHARMA : Notice of conclusion of sales collaboration for GLP-1 receptor..
PU
08/01Nikkei 225 Up 0.7% on Earnings, Wall Street Cues
MT
08/01Japanese shares jump most in nearly two weeks on positive earnings
RE
07/31Japanese shares edge higher with focus on earnings, global growth
RE
07/29TRANSCRIPT : Sumitomo Pharma Co., Ltd., Q1 2023 Earnings Call, Jul 29, 2022
CI
07/29SUMITOMO DAINIPPON PHARMA : Summary of Consolidated Financial Results for the First Quarte..
PU
07/29SUMITOMO DAINIPPON PHARMA : Notice Concerning Finance Income
PU
07/29SUMITOMO DAINIPPON PHARMA : Supplementary Financial Data (IFRS) for the First Quarter of t..
PU
07/29SUMITOMO DAINIPPON PHARMA : Q1 FY2022 (April 1 to June 30, 2022) Conference Call
PU
07/29Sumitomo Pharma Co., Ltd. Provides Earnings Guidance for the Year Ending March 31, 2023
CI
07/29Sumitomo Pharma Co., Ltd. Provides Second Quarter and Year End Dividend Guidance for th..
CI
More news
News in other languages on SUMITOMO DAINIPPON PHARMA CO., LTD.
08/03Sumitomo Pharma Co., Ltd. et Eli Lilly Japan K.K. annoncent la conclusion de la collabo..
08/01Le Nikkei 225 progresse de 0,7 % en raison des résultats et de l'évolution de la Bourse..
07/29Sumitomo Pharma Co., Ltd. fournit des prévisions de bénéfices pour l'année se terminant..
07/29Sumitomo Pharma Co., Ltd. fournit des prévisions de dividendes pour le deuxième trimest..
06/29Sumitomo Pharma Co., Ltd annonce l'avis de création d'une société holding en Chine
More news
Chart SUMITOMO DAINIPPON PHARMA CO., LTD.
Duration : Period :
Sumitomo Dainippon Pharma Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SUMITOMO DAINIPPON PHARMA CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 8
Last Close Price 1 087,00 JPY
Average target price 1 015,00 JPY
Spread / Average Target -6,62%
EPS Revisions
Managers and Directors
Hiroshi Nomura President, Chief Executive Officer & Director
Masayo Tada Chairman
Yoshiharu Ikeda Director, Head-Research & Technology
Isao Shimizu Executive Officer & Senior Research Director
Kenji Ueno Executive Officer & GM-Technology Research
Sector and Competitors
1st jan.Capi. (M$)
SUMITOMO DAINIPPON PHARMA CO., LTD.-17.96%3 200
JOHNSON & JOHNSON-0.52%447 434
ELI LILLY AND COMPANY9.70%287 922
PFIZER, INC.-16.05%279 310
ROCHE HOLDING AG-16.02%275 991
ABBVIE INC.3.58%247 976